Research programme: CFTR inhibitors - Active Pass

Drug Profile

Research programme: CFTR inhibitors - Active Pass

Alternative Names: ABC transporter inhibitors research programme - Active Pass; Research programme: polycystic kidney disease therapy - Active Pass; Research programme: seceretory diarrhoea therapy - Active Pass

Latest Information Update: 04 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Active Pass Pharmaceuticals
  • Class
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diarrhoea; Polycystic kidney disease

Most Recent Events

  • 11 Aug 2005 Preclinical trials in Polycystic kidney disease in Canada (unspecified route)
  • 15 Jun 2004 Discontinued - Preclinical for Age-related macular degeneration in Canada (unspecified route)
  • 15 Jun 2004 Discontinued - Preclinical for Alzheimer's disease in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top